ABEO

Equibles Rating blended score · not investment advice

Overall

Buy

Technical · trend & momentum Buy

◦ 50 / 200-day cross no cross

+ Price vs 200-day avg +21% above

+ Price vs 50-day avg +12% above

◦ RSI (14) 66 · neutral

+ MACD trend positive

◦ 52-week position 65% · mid-range

Sentiment · smart money Bullish

◦ Trend (MA cross) 50d $6 › 200d $5 — 50d above 200d

+ Institutional flow +3% holders QoQ · +16 funds added

− Insider flow Net -$1.1M over 90 days · 100% sells

+ Short interest 24.81% of float · ▼ -1.8% MoM · 16.4 days cover

◦ Volume signal Volume near normal

+ Institution breadth 108 holders — near 3-yr high, broad support

Fundamentals Excellent

+ Revenue growth +258% Y/Y

+ EPS growth +165% Y/Y

− Free cash flow $-84.3M

+ Valuation P/E 6.6 · below peers

+ Balance sheet net cash $58.4M

Blended from price, positioning & fundamentals · daily-close · not investment advice.

Up next

Next earnings call

Aug 12, 2026 Est · unconfirmed · in 5 wks

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed May 13, 2026

AI Brief

TL;DR.

Bullish

Bearish

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Technicals

trend & momentum for long-term holders Buy

0 · 3 · 3

50 / 200-day cross

no cross Neutral

Price vs 200-day avg

+21% above Bullish

Price vs 50-day avg

+12% above Bullish

RSI (14)

66 · neutral Neutral

MACD trend

positive Bullish

52-week position

65% · mid-range Neutral

Market signals — smart money & positioning

Bullish · 3 of 6

Trend (MA cross) No cross

50d $6 › 200d $5 — 50d above 200d

Institutional flow Accumulating

+3% holders QoQ · +16 funds added

Insider flow Distributing

Net -$1.1M over 90 days · 100% sells

Short interest Falling

24.81% of float · ▼ -1.8% MoM · 16.4 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

108 holders — near 3-yr high, broad support

Price context

position in its 52-week range

52-wk low $4 Now $6 · 65% 52-wk high $8

vs 200-day avg +21% vs 50-day avg +12%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
ABEO Abeona Therapeutics Inc. this stock	$359.64M	+19.7%	+258.2%	6.6	24.8%
AKTX Akari Therapeutics Plc	$998.08B	-5.7%	—	—	0.0%
ONC BeOne Medicines Ltd.	$488.96B	+1.9%	+22179.2%	995.1	0.1%
VRTX Vertex Pharmaceuticals Inc / Ma	$134.41B	+16.8%	+46.2%	31.4	1.8%
REGN Regeneron Pharmaceuticals, Inc.	$69.33B	-15.7%	+20.8%	16.1	3.2%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

108

% held: 72.7%
Net QoQ: +1.1M sh
Top holder: Nantahala Capital Managem…

Held Float

View

Held by Funds

Fund positions

View

Short & Settlement

Short Interest Falling

Shares short

14.1M

Days to cover: 16.4d
Change: -255.5K sh

View

Short Volume

Short vol %

64%

As of: Jul 6, 2026

Short Total

View

Fails to Deliver

FTD shares

4.0K

Value: $23.1K
As of: Jun 5, 2026

View

Off-Exchange

Off-exchange %

53.5%

Week of: May 4, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$1.1M

Buyers / Sellers: 0 / 8

Buyers Sellers

View

Financials

Revenue (FY)

$5.8M

Net income (FY): $71.2M
EPS diluted: $1.01

View

Filings

SEC Filings

Latest

Investor Event Transcript

Filed: Jun 30, 2026
This year: 13

View

Proposed Sales

Value

$640.8K

Shares: 102.2K
Filed: Jul 6, 2026

View

Earnings & Events

Earnings Calls

Last call

Jun 12, 2026

View

Performance

	5D	20D	120D	MTD	YTD
ABEO	+12.5%	+8.4%	+21.6%	+2.1%	+19.7%
SPY	+3.1%	-0.8%	+8.2%	+0.6%	+10.2%
vs SPY	+9.4%	+9.2%	+13.3%	+1.5%	+9.6%

Price & Indicators

Technicals

Versus peers

At a glance

Performance